I’d buy this 7%-yielding FTSE 100 dividend stock today!

After recent declines, this FTSE 100 dividend stock looks cheap, despite its growth potential, says this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After the recent market declines, there’s a whole range of FTSE 100 dividend stocks available to investors that yield more than 5%. So when it comes to blue-chip income, investors are spoilt for choice. Indeed, some of these companies offer dividends of 7% or more.

Here’s just one of these FTSE 100 dividend champions that looks undervalued after recent declines.

FTSE 100 dividend income

Insurance group Admiral (LSE: ADM) has earned its reputation as one of the FTSE 100’s top income stocks. Every year, the company pays out almost all of its earnings from operations to shareholders. A combination of regular and special dividends make up the total payout.

By offering a combination of a regular and special dividend, management has the flexibility to vary the payout. It can maintain the regular distribution while cutting the special dividend to retain cash.

Still, despite the FTSE 100 dividend champion’s income credentials, shares in the business have plunged since the beginning of the year. Following this decline, Admiral’s dividend yield has spiked. It currently stands at around 7%. The FTSE 100 average is 4.8%.

Recent trading updates from the UK’s largest insurance company suggest these declines are unwarranted. Last week, the company reported a record set of results, with its UK insurance business performing better than expected. Meanwhile, reduced losses helped improve reserve releases, unlocking additional cash.

Growth ahead

One of the most impressive things about Admiral is its growth potential. The FTSE 100 dividend star has several growth initiatives underway at present. These include the expansion of its personal loans business, its international insurance businesses and comparison website.

Of these three, the comparison website, Confused.com, is the only division that’s currently profitable. However, in the past two or three years, growth at the personal loans business and international insurance operation has exploded. These two divisions should start contributing to the group’s bottom line in the next few years.

Admiral’s expansion should help the company outperform its peers. The UK insurance market is relatively developed and highly competitive. As such, growth is hard to come by. By expanding into other lines of business, the FTSE 100 dividend stock can outgrow its peers, which could push down overall group costs.

Lower costs will allow the business to offer customers better deals, cementing its position as the UK’s largest car insurance business.

The bottom line

Investors have rushed to sell shares in Admiral over the past week or so due to concerns about the impact the Covid-19 outbreak might have on operations. However, Admiral is unlikely to see a sustained drop off in demand for its services as car insurance remains a legal requirement in the UK.

This suggests the company should continue to grow and throw off a healthy income stream for shareholders for the foreseeable future. The virus outbreak is unlikely to have a significant impact on Admiral’s overall operations.

Rupert Hargreaves owns shares in Admiral Group. The Motley Fool UK has recommended Admiral Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »